The dengue human challenge model: Has the time come to accept this challenge?

Journal of Infectious Diseases

Volumn 207, Issue 5, 2013, Pages 697-699

  Durbin, Anna P ^a   Whitehead, Stephen S ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

clinical tria; dengue vaccine; live attenuated tetravalent

Indexed keywords

DENGUE VACCINE;

ANTIBODY RESPONSE; BIOLOGICAL MODEL; DENGUE; DENGUE HUMAN CHALLENGE MODEL; DENGUE VIRUS; DISEASE DURATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNE RESPONSE; NONHUMAN; NOTE; PRIORITY JOURNAL; REPRODUCIBILITY; VACCINATION; VIREMIA; VIRUS STRAIN;

DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; MALE;

EID: 84873654876     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis749     Document Type: Note

References (15)

1. Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus challenge of human subjects previously vaccinated with liveattenuated tetravalent dengue virus vaccines. J Infect Dis 2013; 207:700-8
2. Innis BL, Eckels KH, Kraiselburd E, et al. Virulence of a live dengue virus vaccine candidate: A possible new marker of dengue virus attenuation. J Infect Dis 1988; 158:876-80
3. McKee KT Jr, Bancroft WH, Eckels KH, Redfield RR, Summers PL, Russell PK. Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg 1987; 36:435-42
4. Ashburn PM, Craig CF. Experimental investigations regarding the etiology of dengue fever. J Infect Dis 1907; 4:440-75
5. Sabin A. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50
6. Epstein JE, Rao S, Williams F, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: An update. J Infect Dis 2007; 196:145-54
7. Fries LF, Dillon SB, Hildreth JE, et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-Type H1N1 virus challenge. J Infect Dis 1993; 167:593-601
8. Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P, Hill AV. Bloodstage challenge for malaria vaccine efficacy trials: A pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008; 78:878-83
9. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011; 11:57-64
10. Tribble D, Kaminski R, Cantrell J, et al. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers. Vaccine 2010; 28:6076-85
11. Tribble DR, Baqar S, Carmolli MP, et al. Campylobacter jejuni strain CG8421: A refined model for the study of campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. Clin Infect Dis 2009; 49:1512-9
12. Fox A, Le NM, Simmons CP, et al. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis 2011; 5: E967
13. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181: 2-9
14. Gibbons RV, Kalanarooj S, Jarman RG, et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 2007; 77:910-13
15. Sabchareon AD, Wallace C, Sirivichayakul K, et al. Protective efficacy of the recombinant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67